Personalized Genomics Global Market Report 2025

The personalized genomics market size has grown rapidly in recent years. It will grow from $8.15 billion in 2024 to $9.45 billion in 2025 at a compound annual growth rate (CAGR) of 16%. The historical growth can be linked to increased public awareness of genetic health risks, a surge in chronic and hereditary diseases, enhanced use of AI and machine learning in genomics, a rising interest in lifestyle and nutrition-related genomics, and an expanding role of companion diagnostics in oncology and rare conditions.

The personalized genomics market size is expected to see rapid growth in the next few years. It will grow to $16.97 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. Factors contributing to future growth include heightened interest in tailored medical treatments, expanding popularity of direct-to-consumer (DTC) genetic tests, growing emphasis on preventive care models, increased accessibility to genomic databases and computational tools, and strengthened partnerships between pharmaceutical companies and genomic firms. Key upcoming trends include progress in next-generation sequencing (NGS) methods, the use of AI for decoding genomic information, merging of genomic data with electronic medical records, evolution of bioinformatics technologies, and expansion of cloud-based platforms for genomic data storage and exchange.

The increasing prevalence of chronic and rare diseases is anticipated to drive the growth of the personalized genomics market. Chronic diseases are long-term conditions that require continuous care, while rare diseases are infrequent and often demand specialized medical attention. Lifestyle factors such as unhealthy diets, physical inactivity, and exposure to environmental risks contribute significantly to the rise of these diseases. Personalized genomics plays a crucial role in managing chronic and rare diseases by tailoring treatments to an individual’s genetic profile, enabling more accurate diagnoses, targeted therapies, and improved condition management. For example, in January 2023, the National Center for Biotechnology Information reported that the number of people with at least one chronic disease is projected to rise by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. As a result, the increasing burden of chronic and rare diseases is contributing to the expansion of the personalized genomics market.

Leading companies in the personalized genomics market are focusing on the development of innovative technologies, including personalized genomics platforms, to offer individualized insights into health, wellness, and disease prevention. A personalized genomics platform is designed to analyze a person’s genetic information to provide customized health, nutrition, and treatment recommendations. For instance, in September 2024, Neuberg Diagnostics Private Limited, an India-based diagnostics company, launched Geniee Decode Your DNA, a personalized genomics platform. This platform delivers genetic-based insights that help optimize health, prevent disease, and customize treatments for better health outcomes.

In February 2022, Labcorp Holdings Inc., a U.S.-based life sciences company, acquired Personal Genome Diagnostics Inc. to strengthen its oncology offerings. The acquisition is intended to broaden access to advanced genomic profiling and liquid biopsy technologies, improving the diagnosis and treatment of cancer through personalized methods. Personal Genome Diagnostics Inc. is a U.S.-based cancer genomics company that focuses on identifying tumor biomarkers to personalize cancer therapies.

Major players in the personalized genomics market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., and Pathway Genomics Corporation.

North America was the largest region in the personalized genomics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in personalized genomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the personalized genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Personalized genomics refers to the application of an individual's genetic data to customize healthcare, lifestyle guidance, or risk evaluations for diseases, all based on their distinct DNA makeup. It is utilized in areas such as forecasting disease risks, enhancing drug efficacy, and shaping proactive health strategies.

The primary test categories within personalized genomics include oncology testing, infectious disease testing, neurological testing, cardiovascular testing, and various other diagnostic types. Oncology testing encompasses procedures for identifying, diagnosing, and tracking cancer progression through genetic, molecular, and imaging techniques. Methods used in oncology testing comprise polymerase chain reaction (PCR)-based diagnostics, microarray-based analyses, sequencing-based evaluations, and other cutting-edge technologies. These tools support use cases like diagnostics, precision medicine, reproductive health, wellness, sports nutrition, and lifestyle optimization, serving entities such as hospitals, clinics, research bodies, pharmaceutical and biotech firms, diagnostic labs, and more.

The personalized genomics market research report is one of a collection of recent publications that delivers comprehensive insights into market statistics for personalized genomics, including global market value, regional distribution, competitive landscape, detailed segmentation, current trends, opportunities, and all other information necessary for success in the industry. This report presents a thorough examination of both present conditions and future projections in the personalized genomics market.

The personalized genomics market consists of revenues earned by entities by providing services such as pharmacogenomic services, genetic counseling, and customized fitness plans. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized genomics market also includes sales of genetic testing kits, health risk assessments, and nutrigenomics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.